| Field | Row 1 |
|---|---|
| adsh | 0000014272-25-000091 |
| cik | 14272 |
| name | BRISTOL MYERS SQUIBB CO |
| sic | 2834 |
| countryba | US |
| stprba | NJ |
| cityba | PRINCETON |
| zipba | 08543 |
| bas1 | ROUTE 206 AND PROVINCE LINE ROAD |
| bas2 | |
| baph | 6092524621 |
| countryma | US |
| stprma | NJ |
| cityma | PRINCETON |
| zipma | 08543 |
| mas1 | ROUTE 206 AND PROVINCE LINE ROAD |
| mas2 | |
| countryinc | US |
| stprinc | DE |
| ein | 220790350 |
| former | BRISTOL MYERS CO |
| changed | 19891012 |
| afs | 1-LAF |
| wksi | 0 |
| fye | 1231 |
| form | 10-Q |
| period | 20250331 |
| fy | 2025 |
| fp | Q1 |
| filed | 20250424 |
| accepted | 2025-04-24 11:46:00.0 |
| prevrpt | 0 |
| detail | 1 |
| instance | bmy-20250331_htm.xml |
| nciks | 1 |
| aciks |
| Field Name | Field Description |
|---|---|
| adsh | Accession Number. The 20-character string formed from the 18-digit number assigned by the SEC to each EDGAR submission. |
| cik | Central Index Key (CIK). Ten digit number assigned by the SEC to each registrant that submits filings. |
| name | Name of registrant. This corresponds to the name of the legal entity as recorded in EDGAR as of the filing date. |
| sic | Standard Industrial Classification (SIC). Four digit code assigned by the SEC as of the filing date, indicating the registrant’s type of business. |
| countryba | The ISO 3166-1 country of the registrant's business address. |
| stprba | The state or province of the registrant’s business address, if field countryba is US or CA. |
| cityba | The city of the registrant's business address. |
| zipba | The zip code of the registrant’s business address. |
| bas1 | The first line of the street of the registrant’s business address. |
| bas2 | The second line of the street of the registrant’s business address. |
| baph | The phone number of the registrant’s business address. |
| countryma | The ISO 3166-1 country of the registrant's mailing address. |
| stprma | The state or province of the registrant’s mailing address, if field countryma is US or CA. |
| cityma | The city of the registrant's mailing address. |
| zipma | The zip code of the registrant’s mailing address. |
| mas1 | The first line of the street of the registrant’s mailing address. |
| mas2 | The second line of the street of the registrant’s mailing address. |
| countryinc | The ISO 3166-1 country of incorporation for the registrant. |
| stprinc | The state or province of incorporation for the registrant, if countryinc is US or CA. |
| ein | Employee Identification Number, 9 digit identification number assigned by the Internal Revenue Service to business entities operating in the United States. |
| former | Most recent former name of the registrant, if any. |
| changed | Date of change from the former name, if any. |
| afs | Filer status with the SEC at the time of submission: 1-LAF=Large Accelerated, 2-ACC=Accelerated, 3-SRA=Smaller Reporting Accelerated, 4-NON=Non-Accelerated, 5-SML=Smaller Reporting Filer, NULL=not assigned. |
| wksi | Well Known Seasoned Issuer (WKSI). An issuer that meets specific SEC requirements at some point during a 60-day period preceding the date the issuer satisfies its obligation to update its shelf registration statement. |
| fye | Fiscal Year End Date, rounded to nearest month-end. |
| form | The submission type of the registrant’s filing. |
| period | Balance Sheet Date, rounded to nearest month-end. |
| fy | Fiscal Year Focus (as defined in the EDGAR XBRL Guide Ch. 3.1.8). |
| fp | Fiscal Period Focus (as defined in the EDGAR XBRL Guide Ch. 3.1.8) within Fiscal Year. |
| filed | The date of the registrant’s filing with the Commission. |
| accepted | The acceptance date and time of the registrant’s filing with the Commission. |
| prevrpt | Previous Report – TRUE indicates that the submission information was subsequently amended. |
| detail | TRUE indicates that the XBRL submission contains quantitative disclosures within the footnotes and schedules at the required detail level (e.g., each amount). |
| instance | The name of the submitted XBRL Instance Document. The name often begins with the company ticker symbol. |
| nciks | Number of Central Index Keys (CIK) of registrants (i.e., business units) included in the consolidating entity’s submitted filing. |
| aciks | Additional CIKs of co-registrants included in a consolidating entity’s EDGAR submission, separated by spaces. If there are no other co-registrants (i.e., nciks=1), the value of aciks is NULL. For a very small number of filers, the entire list of co-registrants is too long to fit in the field. Where this is the case, users should refer to the complete submission file for all CIK information. |
| adsh | ddate | tag | value | uom | qtrs | version | segments | coreg | footnote |
|---|---|---|---|---|---|---|---|---|---|
| 0000014272-25-000091 | 20250331 | Accounts Payable Current | 4002000000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000014272-25-000091 | 20241231 | Accumulated Other Comprehensive Income Loss Net Of Tax | -1238000000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000014272-25-000091 | 20241231 | Assets | 92603000000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000014272-25-000091 | 20250331 | Assets Current | 30783000000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000014272-25-000091 | 20231231 | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | 11519000000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000014272-25-000091 | 20250331 | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect | 528000000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000014272-25-000091 | 20250331 | Common Stock Value Outstanding | 292000000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000014272-25-000091 | 20241231 | Accounts Payable Current | 3602000000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000014272-25-000091 | 20250331 | Accumulated Other Comprehensive Income Loss Net Of Tax | -1424000000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000014272-25-000091 | 20250331 | Amortizationof Acquired Intangible Assets | 830000000.0000 | USD | 1 | 0000014272-25-000091 | |||
| 0000014272-25-000091 | 20250331 | Available For Sale Securities Debt Securities Current | 907000000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000014272-25-000091 | 20240331 | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect | -2185000000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000014272-25-000091 | 20250331 | Deferred Income Tax Assets Net | 3997000000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000014272-25-000091 | 20250331 | Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest | 2971000000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000014272-25-000091 | 20250331 | Increase Decrease In Accrued Income Taxes Payable | 54000000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000014272-25-000091 | 20250331 | Increase Decrease In Other Accrued Liabilities | -627000000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000014272-25-000091 | 20240331 | Increase Decrease In Receivables | -479000000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000014272-25-000091 | 20250331 | Increase Decrease In Receivables | -15000000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000014272-25-000091 | 20241231 | Minority Interest | 53000000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000014272-25-000091 | 20240331 | Net Cash Provided By Used In Financing Activities | 14644000000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000014272-25-000091 | 20250331 | Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax | 1000000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000014272-25-000091 | 20240331 | Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Net Of Tax | -13000000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000014272-25-000091 | 20240331 | Other Noncash Income Expense | -23000000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000014272-25-000091 | 20240331 | Payments Of Dividends | 1212000000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000014272-25-000091 | 20241231 | Preferred Stock Value | 0.0000 | USD | 0 | us-gaap/2024 | |||
| 0000014272-25-000091 | 20240331 | Revenues | 3720000000.0000 | USD | 1 | us-gaap/2024 | Product Or Service= Eliquis; | ||
| 0000014272-25-000091 | 20240331 | Revenues | 21000000.0000 | USD | 1 | us-gaap/2024 | Product Or Service= Krazati; | ||
| 0000014272-25-000091 | 20240331 | Revenues | 7073000000.0000 | USD | 1 | us-gaap/2024 | Product Or Service= Legacy Brands; | ||
| 0000014272-25-000091 | 20240331 | Revenues | 2078000000.0000 | USD | 1 | us-gaap/2024 | Product Or Service= Opdivo; | ||
| 0000014272-25-000091 | 20240331 | Revenues | 228000000.0000 | USD | 1 | us-gaap/2024 | Product Or Service= Other Legacy Brands; | ||
| 0000014272-25-000091 | 20250331 | Revenues | 403000000.0000 | USD | 1 | us-gaap/2024 | Product Or Service= Other Growth Brands; | ||
| 0000014272-25-000091 | 20250331 | Revenues | 199000000.0000 | USD | 1 | us-gaap/2024 | Product Or Service= Other Legacy Brands; | ||
| 0000014272-25-000091 | 20250331 | Revenues | 107000000.0000 | USD | 1 | us-gaap/2024 | Product Or Service= Zeposia; | ||
| 0000014272-25-000091 | 20240331 | Share Based Compensation | 133000000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000014272-25-000091 | 20240331 | Stockholders Equity Including Portion Attributable To Noncontrolling Interest | -43697000000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Treasury Stock Common; | ||
| 0000014272-25-000091 | 20240331 | Revenues | 798000000.0000 | USD | 1 | us-gaap/2024 | Product Or Service= Orencia; | ||
| 0000014272-25-000091 | 20250331 | Debt Current | 3554000000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000014272-25-000091 | 20241231 | Deferred Income Tax Liabilities Net | 369000000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000014272-25-000091 | 20240331 | Earnings Per Share Diluted | -5.8900 | USD | 1 | us-gaap/2024 | |||
| 0000014272-25-000091 | 20240331 | Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | -45000000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000014272-25-000091 | 20250331 | Goodwill | 21737000000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000014272-25-000091 | 20241231 | Intangible Assets Net Excluding Goodwill | 400000000.0000 | USD | 0 | us-gaap/2024 | Finite Lived Intangible Assets By Major Class= Computer Software Intangible Asset; | ||
| 0000014272-25-000091 | 20250331 | Intangible Assets Net Excluding Goodwill | 22486000000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000014272-25-000091 | 20250331 | Intangible Assets Net Excluding Goodwill | 389000000.0000 | USD | 0 | us-gaap/2024 | Finite Lived Intangible Assets By Major Class= Computer Software Intangible Asset; | ||
| 0000014272-25-000091 | 20250331 | Intangible Assets Net Excluding Goodwill | 7985000000.0000 | USD | 0 | us-gaap/2024 | Indefinite Lived Intangible Assets By Major Class= In Process Research And Development; | ||
| 0000014272-25-000091 | 20250331 | Long Term Debt Noncurrent | 46157000000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000014272-25-000091 | 20240331 | Net Cash Provided By Used In Investing Activities | -19618000000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000014272-25-000091 | 20241231 | Other Assets Noncurrent | 6105000000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000014272-25-000091 | 20240331 | Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax | 191000000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000014272-25-000091 | 20250331 | Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Net Of Tax | -1000000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000014272-25-000091 | 20240331 | Proceeds From Issuance Of Long Term Debt | 12883000000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000014272-25-000091 | 20250331 | Proceeds From Sale Of Equity Securities Fv Ni | 12000000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000014272-25-000091 | 20250331 | Profit Loss | 2462000000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000014272-25-000091 | 20250331 | Revenues | 105000000.0000 | USD | 1 | us-gaap/2024 | Product Or Service= Abraxane; | ||
| 0000014272-25-000091 | 20250331 | Revenues | 3565000000.0000 | USD | 1 | us-gaap/2024 | Product Or Service= Eliquis; | ||
| 0000014272-25-000091 | 20250331 | Revenues | 658000000.0000 | USD | 1 | us-gaap/2024 | Product Or Service= Pomalyst Imnovid; | ||
| 0000014272-25-000091 | 20250331 | Revenues | 175000000.0000 | USD | 1 | us-gaap/2024 | Product Or Service= Sprycel; | ||
| 0000014272-25-000091 | 20241231 | Stockholders Equity | 16335000000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000014272-25-000091 | 20231231 | Stockholders Equity Including Portion Attributable To Noncontrolling Interest | 28766000000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Retained Earnings; | ||
| 0000014272-25-000091 | 20240331 | Stockholders Equity Including Portion Attributable To Noncontrolling Interest | -1400000000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Accumulated Other Comprehensive Income; | ||
| 0000014272-25-000091 | 20241231 | Stockholders Equity Including Portion Attributable To Noncontrolling Interest | 16388000000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000014272-25-000091 | 20250331 | Stockholders Equity Including Portion Attributable To Noncontrolling Interest | 17448000000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000014272-25-000091 | 20250331 | Stockholders Equity Including Portion Attributable To Noncontrolling Interest | 59000000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Noncontrolling Interest; | ||
| 0000014272-25-000091 | 20250331 | Stockholders Equity Including Portion Attributable To Noncontrolling Interest | -43597000000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Treasury Stock Common; | ||
| 0000014272-25-000091 | 20241231 | Treasury Stock Common Value | 43655000000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000014272-25-000091 | 20240331 | Acquired I P R D | 12949000000.0000 | USD | 1 | 0000014272-25-000091 | |||
| 0000014272-25-000091 | 20241231 | Additional Paid In Capital | 46024000000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000014272-25-000091 | 20250331 | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | 10875000000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000014272-25-000091 | 20241231 | Debt Current | 2046000000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000014272-25-000091 | 20241231 | Deferred Income Tax Assets Net | 4236000000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000014272-25-000091 | 20240331 | Divestitureandotherproceeds | 241000000.0000 | USD | 1 | 0000014272-25-000091 | |||
| 0000014272-25-000091 | 20250331 | Equity Method Investment Realized Gain Loss On Disposal | -78000000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000014272-25-000091 | 20240331 | Increase Decrease In Accounts Payable | 300000000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000014272-25-000091 | 20240331 | Increase Decrease In Accrued Income Taxes Payable | 910000000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000014272-25-000091 | 20250331 | Liabilities And Stockholders Equity | 92427000000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000014272-25-000091 | 20250331 | Liabilities Current | 24070000000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000014272-25-000091 | 20240331 | Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax | -56000000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000014272-25-000091 | 20240331 | Other Comprehensive Income Loss Net Of Tax | 146000000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000014272-25-000091 | 20250331 | Other Comprehensive Income Loss Net Of Tax | -185000000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000014272-25-000091 | 20250331 | Other Comprehensive Income Loss Net Of Tax | -185000000.0000 | USD | 1 | us-gaap/2024 | Equity Components= Accumulated Other Comprehensive Income; | ||
| 0000014272-25-000091 | 20250331 | Other Liabilities Current | 16514000000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000014272-25-000091 | 20250331 | Payments Of Dividends | 1258000000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000014272-25-000091 | 20250331 | Receivables Net Current | 170000000.0000 | USD | 0 | us-gaap/2024 | Type Of Arrangement= Collaborative Arrangement; | ||
| 0000014272-25-000091 | 20240331 | Research And Development Expense | 1083000000.0000 | USD | 1 | us-gaap/2024 | Nature Of Expense= Drug Development; | ||
| 0000014272-25-000091 | 20240331 | Research And Development Expense | 1228000000.0000 | USD | 1 | us-gaap/2024 | Nature Of Expense= Research And Development Expense Other; | ||
| 0000014272-25-000091 | 20250331 | Research And Development Expense | 314000000.0000 | USD | 1 | us-gaap/2024 | Nature Of Expense= Other Research; | ||
| 0000014272-25-000091 | 20250331 | Research And Development Expense | 861000000.0000 | USD | 1 | us-gaap/2024 | Nature Of Expense= Research And Development Expense Other; | ||
| 0000014272-25-000091 | 20241231 | Retained Earnings Accumulated Deficit | 14912000000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000014272-25-000091 | 20240331 | Revenues | 134000000.0000 | USD | 1 | us-gaap/2024 | Product Or Service= Alliance Revenues; Type Of Arrangement= Collaborative Arrangement; | ||
| 0000014272-25-000091 | 20240331 | Revenues | 107000000.0000 | USD | 1 | us-gaap/2024 | Product Or Service= Breyanzi; | ||
| 0000014272-25-000091 | 20240331 | Revenues | 0.0000 | USD | 1 | us-gaap/2024 | Product Or Service= Opdivo Ovantig; | ||
| 0000014272-25-000091 | 20240331 | Revenues | 172000000.0000 | USD | 1 | us-gaap/2024 | Product Or Service= Other Revenues; | ||
| 0000014272-25-000091 | 20240331 | Revenues | 354000000.0000 | USD | 1 | us-gaap/2024 | Product Or Service= Reblozyl; | ||
| 0000014272-25-000091 | 20240331 | Revenues | 1669000000.0000 | USD | 1 | us-gaap/2024 | Product Or Service= Revlimid; | ||
| 0000014272-25-000091 | 20250331 | Revenues | 3110000000.0000 | USD | 1 | us-gaap/2024 | Geographical= International; | ||
| 0000014272-25-000091 | 20250331 | Revenues | 263000000.0000 | USD | 1 | us-gaap/2024 | Product Or Service= Breyanzi; | ||
| 0000014272-25-000091 | 20250331 | Revenues | 19874000000.0000 | USD | 1 | us-gaap/2024 | Product Or Service= Sales Revenue Gross; | ||
| 0000014272-25-000091 | 20240331 | Selling General And Administrative Expense | 79000000.0000 | USD | 1 | us-gaap/2024 | Type Of Arrangement= Collaborative Arrangement; | ||
| 0000014272-25-000091 | 20250331 | Stockholders Equity Including Portion Attributable To Noncontrolling Interest | -1424000000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Accumulated Other Comprehensive Income; | ||
| 0000014272-25-000091 | 20250331 | Research And Development Expense | 1081000000.0000 | USD | 1 | us-gaap/2024 | Nature Of Expense= Drug Development; | ||
| 0000014272-25-000091 | 20250331 | Retained Earnings Accumulated Deficit | 16106000000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000014272-25-000091 | 20240331 | Revenues | 82000000.0000 | USD | 1 | us-gaap/2024 | Product Or Service= Abecma; | ||
| 0000014272-25-000091 | 20240331 | Revenues | 306000000.0000 | USD | 1 | us-gaap/2024 | Product Or Service= Allianceandotherrevenues; | ||
| 0000014272-25-000091 | 20240331 | Revenues | 4792000000.0000 | USD | 1 | us-gaap/2024 | Product Or Service= Growth Brands; | ||
| 0000014272-25-000091 | 20240331 | Revenues | 19295000000.0000 | USD | 1 | us-gaap/2024 | Product Or Service= Sales Revenue Gross; | ||
| 0000014272-25-000091 | 20240331 | Revenues | 110000000.0000 | USD | 1 | us-gaap/2024 | Product Or Service= Zeposia; | ||
| 0000014272-25-000091 | 20250331 | Revenues | 27000000.0000 | USD | 1 | us-gaap/2024 | Product Or Service= Cobenfy; | ||
| 0000014272-25-000091 | 20250331 | Revenues | 5638000000.0000 | USD | 1 | us-gaap/2024 | Product Or Service= Legacy Brands; | ||
| 0000014272-25-000091 | 20250331 | Revenues | 10886000000.0000 | USD | 1 | us-gaap/2024 | Product Or Service= Net Product Sales; | ||
| 0000014272-25-000091 | 20250331 | Revenues | 9000000.0000 | USD | 1 | us-gaap/2024 | Product Or Service= Opdivo Ovantig; | ||
| 0000014272-25-000091 | 20250331 | Revenues | 3723000000.0000 | USD | 1 | us-gaap/2024 | Type Of Arrangement= Collaborative Arrangement; | ||
| 0000014272-25-000091 | 20250331 | Selling General And Administrative Expense | 65000000.0000 | USD | 1 | us-gaap/2024 | Type Of Arrangement= Collaborative Arrangement; | ||
| 0000014272-25-000091 | 20250331 | Share Based Compensation | 144000000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000014272-25-000091 | 20231231 | Stockholders Equity Including Portion Attributable To Noncontrolling Interest | 292000000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Common Stock; | ||
| 0000014272-25-000091 | 20231231 | Stockholders Equity Including Portion Attributable To Noncontrolling Interest | 55000000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Noncontrolling Interest; | ||
| 0000014272-25-000091 | 20240331 | Stockholders Equity Including Portion Attributable To Noncontrolling Interest | 58000000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Noncontrolling Interest; | ||
| 0000014272-25-000091 | 20241231 | Stockholders Equity Including Portion Attributable To Noncontrolling Interest | -1238000000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Accumulated Other Comprehensive Income; | ||
| 0000014272-25-000091 | 20250331 | Stockholders Equity Including Portion Attributable To Noncontrolling Interest | 46011000000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Additional Paid In Capital; | ||
| 0000014272-25-000091 | 20250331 | Stockholders Equity Including Portion Attributable To Noncontrolling Interest | 292000000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Common Stock; | ||
| 0000014272-25-000091 | 20241231 | Available For Sale Securities Debt Securities Current | 513000000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000014272-25-000091 | 20250331 | Cash And Cash Equivalents At Carrying Value | 10875000000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000014272-25-000091 | 20241231 | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | 10347000000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000014272-25-000091 | 20240331 | Comprehensive Income Net Of Tax | -11765000000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000014272-25-000091 | 20250331 | Comprehensive Income Net Of Tax | 2271000000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000014272-25-000091 | 20250331 | Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest | 2277000000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000014272-25-000091 | 20240331 | Deferred Income Tax Expense Benefit | -711000000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000014272-25-000091 | 20250331 | Deferred Income Tax Expense Benefit | 223000000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000014272-25-000091 | 20240331 | Equity Method Investment Realized Gain Loss On Disposal | 102000000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000014272-25-000091 | 20240331 | Income Tax Expense Benefit | 392000000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000014272-25-000091 | 20240331 | Increase Decrease In Inventories | 218000000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000014272-25-000091 | 20240331 | Increase Decrease In Other Accrued Liabilities | -665000000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000014272-25-000091 | 20240331 | Increase Decrease In Other Operating Capital Net | 608000000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000014272-25-000091 | 20250331 | Liabilities | 74979000000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000014272-25-000091 | 20241231 | Liabilities Current | 23774000000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000014272-25-000091 | 20250331 | Net Income Loss | 2456000000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000014272-25-000091 | 20250331 | Other Assets Current | 5534000000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000014272-25-000091 | 20250331 | Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax | 28000000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000014272-25-000091 | 20250331 | Other Nonoperating Income Expense | 12000000.0000 | USD | 1 | us-gaap/2024 | Type Of Arrangement= Collaborative Arrangement; | ||
| 0000014272-25-000091 | 20240331 | Payments To Acquire Marketable Securities | 274000000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000014272-25-000091 | 20240331 | Profit Loss | -11911000000.0000 | USD | 1 | us-gaap/2024 | Equity Components= Retained Earnings; | ||
| 0000014272-25-000091 | 20250331 | Property Plant And Equipment Net | 7213000000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000014272-25-000091 | 20241231 | Available For Sale Securities Debt Securities Noncurrent | 320000000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000014272-25-000091 | 20241231 | Commitments And Contingencies | USD | 0 | us-gaap/2024 | ||||
| 0000014272-25-000091 | 20240331 | Cost Of Goods And Services Sold | 2932000000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000014272-25-000091 | 20250331 | Cost Of Goods And Services Sold | 3033000000.0000 | USD | 1 | us-gaap/2024 | Excludes amortization of acquired intangible assets | ||
| 0000014272-25-000091 | 20250331 | Costs And Expenses | 8230000000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000014272-25-000091 | 20250331 | Deferred Income Tax Liabilities Net | 276000000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000014272-25-000091 | 20250331 | Depreciation Depletion And Amortization | 1012000000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000014272-25-000091 | 20250331 | Divestitureandotherproceeds | 243000000.0000 | USD | 1 | 0000014272-25-000091 | |||
| 0000014272-25-000091 | 20250331 | Increase Decrease In Inventories | 169000000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000014272-25-000091 | 20241231 | Intangible Assets Net Excluding Goodwill | 13217000000.0000 | USD | 0 | us-gaap/2024 | Finite Lived Intangible Assets By Major Class= Acquired Marketed Product Rights; | ||
| 0000014272-25-000091 | 20250331 | Intangible Assets Net Excluding Goodwill | 1622000000.0000 | USD | 0 | us-gaap/2024 | Finite Lived Intangible Assets By Major Class= Technology Based Intangible Assets; | ||
| 0000014272-25-000091 | 20250331 | Net Cash Provided By Used In Financing Activities | -993000000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000014272-25-000091 | 20240331 | Other Comprehensive Income Loss Net Of Tax | 146000000.0000 | USD | 1 | us-gaap/2024 | Equity Components= Accumulated Other Comprehensive Income; | ||
| 0000014272-25-000091 | 20240331 | Other Nonoperating Income Expense | -81000000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000014272-25-000091 | 20250331 | Payments To Acquire Property Plant And Equipment | 260000000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000014272-25-000091 | 20250331 | Preferred Stock Value | 0.0000 | USD | 0 | us-gaap/2024 | |||
| 0000014272-25-000091 | 20250331 | Proceeds From Other Short Term Debt | 368000000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000014272-25-000091 | 20240331 | Profit Loss | -11908000000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000014272-25-000091 | 20250331 | Research And Development Expense | 2257000000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000014272-25-000091 | 20240331 | Revenues | 3190000000.0000 | USD | 1 | us-gaap/2024 | Geographical= International; | ||
| 0000014272-25-000091 | 20240331 | Revenues | 583000000.0000 | USD | 1 | us-gaap/2024 | Product Or Service= Yervoy; | ||
| 0000014272-25-000091 | 20250331 | Revenues | 48000000.0000 | USD | 1 | us-gaap/2024 | Product Or Service= Krazati; | ||
| 0000014272-25-000091 | 20250331 | Stockholders Equity | 17389000000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000014272-25-000091 | 20231231 | Stockholders Equity Including Portion Attributable To Noncontrolling Interest | 45684000000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Additional Paid In Capital; | ||
| 0000014272-25-000091 | 20240331 | Stockholders Equity Including Portion Attributable To Noncontrolling Interest | 45655000000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Additional Paid In Capital; | ||
| 0000014272-25-000091 | 20240331 | Stockholders Equity Including Portion Attributable To Noncontrolling Interest | 292000000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Common Stock; | ||
| 0000014272-25-000091 | 20241231 | Stockholders Equity Including Portion Attributable To Noncontrolling Interest | 46024000000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Additional Paid In Capital; | ||
| 0000014272-25-000091 | 20241231 | Stockholders Equity Including Portion Attributable To Noncontrolling Interest | 53000000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Noncontrolling Interest; | ||
| 0000014272-25-000091 | 20241231 | Receivables Net Current | 10747000000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000014272-25-000091 | 20241231 | Receivables Net Current | 221000000.0000 | USD | 0 | us-gaap/2024 | Type Of Arrangement= Collaborative Arrangement; | ||
| 0000014272-25-000091 | 20240331 | Research And Development Expense | 384000000.0000 | USD | 1 | us-gaap/2024 | Nature Of Expense= Other Research; | ||
| 0000014272-25-000091 | 20240331 | Revenues | 199000000.0000 | USD | 1 | us-gaap/2024 | Geographical= Other Region; | ||
| 0000014272-25-000091 | 20240331 | Revenues | 8476000000.0000 | USD | 1 | us-gaap/2024 | Geographical= U S; | ||
| 0000014272-25-000091 | 20240331 | Revenues | 84000000.0000 | USD | 1 | us-gaap/2024 | Product Or Service= Camzyos; | ||
| 0000014272-25-000091 | 20240331 | Revenues | 3762000000.0000 | USD | 1 | us-gaap/2024 | Product Or Service= Net Product Sales; Type Of Arrangement= Collaborative Arrangement; | ||
| 0000014272-25-000091 | 20240331 | Revenues | 206000000.0000 | USD | 1 | us-gaap/2024 | Product Or Service= Opdualag; | ||
| 0000014272-25-000091 | 20240331 | Revenues | 865000000.0000 | USD | 1 | us-gaap/2024 | Product Or Service= Pomalyst Imnovid; | ||
| 0000014272-25-000091 | 20250331 | Revenues | 218000000.0000 | USD | 1 | us-gaap/2024 | Geographical= Other Region; | ||
| 0000014272-25-000091 | 20250331 | Revenues | 7873000000.0000 | USD | 1 | us-gaap/2024 | Geographical= U S; | ||
| 0000014272-25-000091 | 20250331 | Revenues | 103000000.0000 | USD | 1 | us-gaap/2024 | Product Or Service= Abecma; | ||
| 0000014272-25-000091 | 20250331 | Revenues | 88000000.0000 | USD | 1 | us-gaap/2024 | Product Or Service= Alliance Revenues; Type Of Arrangement= Collaborative Arrangement; | ||
| 0000014272-25-000091 | 20250331 | Revenues | 159000000.0000 | USD | 1 | us-gaap/2024 | Product Or Service= Camzyos; | ||
| 0000014272-25-000091 | 20250331 | Revenues | 5563000000.0000 | USD | 1 | us-gaap/2024 | Product Or Service= Growth Brands; | ||
| 0000014272-25-000091 | 20250331 | Revenues | 2265000000.0000 | USD | 1 | us-gaap/2024 | Product Or Service= Opdivo; | ||
| 0000014272-25-000091 | 20250331 | Revenues | 252000000.0000 | USD | 1 | us-gaap/2024 | Product Or Service= Opdualag; | ||
| 0000014272-25-000091 | 20250331 | Revenues | 227000000.0000 | USD | 1 | us-gaap/2024 | Product Or Service= Other Revenues; | ||
| 0000014272-25-000091 | 20250331 | Revenues | 55000000.0000 | USD | 1 | us-gaap/2024 | Product Or Service= Sotyktu; | ||
| 0000014272-25-000091 | 20241231 | Stockholders Equity Including Portion Attributable To Noncontrolling Interest | 292000000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Common Stock; | ||
| 0000014272-25-000091 | 20241231 | Stockholders Equity Including Portion Attributable To Noncontrolling Interest | 14912000000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Retained Earnings; | ||
| 0000014272-25-000091 | 20241231 | Stockholders Equity Including Portion Attributable To Noncontrolling Interest | -43655000000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Treasury Stock Common; | ||
| 0000014272-25-000091 | 20250331 | Treasury Stock Common Value | 43597000000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000014272-25-000091 | 20250331 | Additional Paid In Capital | 46011000000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000014272-25-000091 | 20240331 | Amortizationof Acquired Intangible Assets | 2357000000.0000 | USD | 1 | 0000014272-25-000091 | |||
| 0000014272-25-000091 | 20250331 | Assets | 92427000000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000014272-25-000091 | 20241231 | Assets Current | 29780000000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000014272-25-000091 | 20240331 | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | 9334000000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000014272-25-000091 | 20240331 | Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest | 3000000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000014272-25-000091 | 20250331 | Cost Of Goods And Services Sold | 1788000000.0000 | USD | 1 | us-gaap/2024 | Type Of Arrangement= Collaborative Arrangement; | ||
| 0000014272-25-000091 | 20250331 | Divestituregainsandroyalties | 292000000.0000 | USD | 1 | 0000014272-25-000091 | |||
| 0000014272-25-000091 | 20240331 | Earnings Per Share Basic | -5.8900 | USD | 1 | us-gaap/2024 | |||
| 0000014272-25-000091 | 20250331 | Earnings Per Share Basic | 1.2100 | USD | 1 | us-gaap/2024 | |||
| 0000014272-25-000091 | 20241231 | Goodwill | 21719000000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000014272-25-000091 | 20250331 | Increase Decrease In Other Operating Capital Net | 1059000000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000014272-25-000091 | 20241231 | Intangible Assets Net Excluding Goodwill | 23307000000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000014272-25-000091 | 20241231 | Intangible Assets Net Excluding Goodwill | 1705000000.0000 | USD | 0 | us-gaap/2024 | Finite Lived Intangible Assets By Major Class= Technology Based Intangible Assets; | ||
| 0000014272-25-000091 | 20250331 | Intangible Assets Net Excluding Goodwill | 12490000000.0000 | USD | 0 | us-gaap/2024 | Finite Lived Intangible Assets By Major Class= Acquired Marketed Product Rights; | ||
| 0000014272-25-000091 | 20250331 | Inventory Net | 2666000000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000014272-25-000091 | 20241231 | Long Term Debt Noncurrent | 47603000000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000014272-25-000091 | 20250331 | Net Cash Provided By Used In Operating Activities | 1954000000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000014272-25-000091 | 20250331 | Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax | -215000000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000014272-25-000091 | 20250331 | Other Noncash Income Expense | -10000000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000014272-25-000091 | 20250331 | Other Nonoperating Income Expense | -339000000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000014272-25-000091 | 20250331 | Payments For Proceeds From Stock Option Exercises And Other Adjustments | -103000000.0000 | USD | 1 | 0000014272-25-000091 | |||
| 0000014272-25-000091 | 20250331 | Proceeds From Issuance Of Long Term Debt | 0.0000 | USD | 1 | us-gaap/2024 | |||
| 0000014272-25-000091 | 20240331 | Proceeds From Other Short Term Debt | 83000000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000014272-25-000091 | 20240331 | Proceeds From Sale Of Equity Securities Fv Ni | 5000000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000014272-25-000091 | 20240331 | Profit Loss | 3000000.0000 | USD | 1 | us-gaap/2024 | Equity Components= Noncontrolling Interest; | ||
| 0000014272-25-000091 | 20250331 | Receivables Net Current | 10801000000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000014272-25-000091 | 20240331 | Revenues | 44000000.0000 | USD | 1 | us-gaap/2024 | Product Or Service= Sotyktu; | ||
| 0000014272-25-000091 | 20240331 | Revenues | 3896000000.0000 | USD | 1 | us-gaap/2024 | Type Of Arrangement= Collaborative Arrangement; | ||
| 0000014272-25-000091 | 20250331 | Revenues | 11201000000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000014272-25-000091 | 20250331 | Revenues | 315000000.0000 | USD | 1 | us-gaap/2024 | Product Or Service= Allianceandotherrevenues; | ||
| 0000014272-25-000091 | 20250331 | Revenues | 770000000.0000 | USD | 1 | us-gaap/2024 | Product Or Service= Orencia; | ||
| 0000014272-25-000091 | 20250331 | Revenues | 478000000.0000 | USD | 1 | us-gaap/2024 | Product Or Service= Reblozyl; | ||
| 0000014272-25-000091 | 20250331 | Selling General And Administrative Expense | 1584000000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000014272-25-000091 | 20231231 | Stockholders Equity Including Portion Attributable To Noncontrolling Interest | -43766000000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Treasury Stock Common; | ||
| 0000014272-25-000091 | 20240331 | Stockholders Equity Including Portion Attributable To Noncontrolling Interest | 15640000000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Retained Earnings; | ||
| 0000014272-25-000091 | 20250331 | Stockholders Equity Including Portion Attributable To Noncontrolling Interest | 16106000000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Retained Earnings; | ||
| 0000014272-25-000091 | 20241231 | Accounts Payable Current | 1578000000.0000 | USD | 0 | us-gaap/2024 | Type Of Arrangement= Collaborative Arrangement; | ||
| 0000014272-25-000091 | 20250331 | Acquired I P R D | 188000000.0000 | USD | 1 | 0000014272-25-000091 | |||
| 0000014272-25-000091 | 20250331 | Available For Sale Securities Debt Securities Noncurrent | 344000000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000014272-25-000091 | 20250331 | Commitments And Contingencies | USD | 0 | us-gaap/2024 | ||||
| 0000014272-25-000091 | 20240331 | Depreciation Depletion And Amortization | 2532000000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000014272-25-000091 | 20240331 | Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest | -11516000000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000014272-25-000091 | 20250331 | Increase Decrease In Accounts Payable | -85000000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000014272-25-000091 | 20241231 | Intangible Assets Net Excluding Goodwill | 7985000000.0000 | USD | 0 | us-gaap/2024 | Indefinite Lived Intangible Assets By Major Class= In Process Research And Development; | ||
| 0000014272-25-000091 | 20241231 | Liabilities | 76215000000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000014272-25-000091 | 20241231 | Liabilities And Stockholders Equity | 92603000000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000014272-25-000091 | 20250331 | Net Cash Provided By Used In Investing Activities | -499000000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000014272-25-000091 | 20240331 | Net Cash Provided By Used In Operating Activities | 2834000000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000014272-25-000091 | 20250331 | Other Assets Noncurrent | 5866000000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000014272-25-000091 | 20240331 | Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax | -2000000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000014272-25-000091 | 20250331 | Other Liabilities Noncurrent | 4477000000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000014272-25-000091 | 20240331 | Other Nonoperating Income Expense | 12000000.0000 | USD | 1 | us-gaap/2024 | Type Of Arrangement= Collaborative Arrangement; | ||
| 0000014272-25-000091 | 20240331 | Payments For Proceeds From Stock Option Exercises And Other Adjustments | -97000000.0000 | USD | 1 | 0000014272-25-000091 | |||
| 0000014272-25-000091 | 20240331 | Payments To Acquire Businesses Net Of Cash Acquired | 20053000000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000014272-25-000091 | 20250331 | Proceeds From Issuance Of Commercial Paper | 0.0000 | USD | 1 | us-gaap/2024 | |||
| 0000014272-25-000091 | 20250331 | Profit Loss | 6000000.0000 | USD | 1 | us-gaap/2024 | Equity Components= Noncontrolling Interest; | ||
| 0000014272-25-000091 | 20240331 | Revenues | 11865000000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000014272-25-000091 | 20240331 | Revenues | 217000000.0000 | USD | 1 | us-gaap/2024 | Product Or Service= Abraxane; | ||
| 0000014272-25-000091 | 20240331 | Revenues | 325000000.0000 | USD | 1 | us-gaap/2024 | Product Or Service= Other Growth Brands; | ||
| 0000014272-25-000091 | 20240331 | Revenues | 11559000000.0000 | USD | 1 | us-gaap/2024 | Product Or Service= Net Product Sales; | ||
| 0000014272-25-000091 | 20250331 | Accounts Payable Current | 1762000000.0000 | USD | 0 | us-gaap/2024 | Type Of Arrangement= Collaborative Arrangement; | ||
| 0000014272-25-000091 | 20241231 | Cash And Cash Equivalents At Carrying Value | 10346000000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000014272-25-000091 | 20241231 | Common Stock Value Outstanding | 292000000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000014272-25-000091 | 20250331 | Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest | 6000000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000014272-25-000091 | 20240331 | Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest | -11762000000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000014272-25-000091 | 20240331 | Cost Of Goods And Services Sold | 1825000000.0000 | USD | 1 | us-gaap/2024 | Type Of Arrangement= Collaborative Arrangement; | ||
| 0000014272-25-000091 | 20240331 | Costs And Expenses | 23381000000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000014272-25-000091 | 20240331 | Divestituregainsandroyalties | 280000000.0000 | USD | 1 | 0000014272-25-000091 | |||
| 0000014272-25-000091 | 20250331 | Earnings Per Share Diluted | 1.2000 | USD | 1 | us-gaap/2024 | |||
| 0000014272-25-000091 | 20250331 | Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | 66000000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000014272-25-000091 | 20250331 | Income Tax Expense Benefit | 509000000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000014272-25-000091 | 20241231 | Inventory Net | 2557000000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000014272-25-000091 | 20250331 | Minority Interest | 59000000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000014272-25-000091 | 20240331 | Net Income Loss | -11911000000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000014272-25-000091 | 20241231 | Other Assets Current | 5617000000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000014272-25-000091 | 20241231 | Other Liabilities Current | 18126000000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000014272-25-000091 | 20241231 | Other Liabilities Noncurrent | 4469000000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000014272-25-000091 | 20250331 | Payments To Acquire Businesses Net Of Cash Acquired | 78000000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000014272-25-000091 | 20250331 | Payments To Acquire Marketable Securities | 636000000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000014272-25-000091 | 20240331 | Payments To Acquire Property Plant And Equipment | 284000000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000014272-25-000091 | 20240331 | Proceeds From Issuance Of Commercial Paper | 2987000000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000014272-25-000091 | 20240331 | Proceeds From Sale And Maturity Of Available For Sale Securities | 747000000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000014272-25-000091 | 20250331 | Proceeds From Sale And Maturity Of Available For Sale Securities | 220000000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000014272-25-000091 | 20250331 | Profit Loss | 2456000000.0000 | USD | 1 | us-gaap/2024 | Equity Components= Retained Earnings; | ||
| 0000014272-25-000091 | 20241231 | Property Plant And Equipment Net | 7136000000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000014272-25-000091 | 20240331 | Research And Development Expense | 2695000000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000014272-25-000091 | 20240331 | Revenues | 0.0000 | USD | 1 | us-gaap/2024 | Product Or Service= Cobenfy; | ||
| 0000014272-25-000091 | 20240331 | Revenues | 374000000.0000 | USD | 1 | us-gaap/2024 | Product Or Service= Sprycel; | ||
| 0000014272-25-000091 | 20250331 | Revenues | 3635000000.0000 | USD | 1 | us-gaap/2024 | Product Or Service= Net Product Sales; Type Of Arrangement= Collaborative Arrangement; | ||
| 0000014272-25-000091 | 20250331 | Revenues | 936000000.0000 | USD | 1 | us-gaap/2024 | Product Or Service= Revlimid; | ||
| 0000014272-25-000091 | 20250331 | Revenues | 624000000.0000 | USD | 1 | us-gaap/2024 | Product Or Service= Yervoy; | ||
| 0000014272-25-000091 | 20240331 | Selling General And Administrative Expense | 2367000000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000014272-25-000091 | 20231231 | Stockholders Equity Including Portion Attributable To Noncontrolling Interest | -1546000000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Accumulated Other Comprehensive Income; |
| Field Name | Field Description |
|---|---|
| adsh | Accession Number. The 20-character string formed from the 18-digit number assigned by the SEC to each EDGAR submission. |
| tag | The unique identifier (name) for a tag in a specific taxonomy release. |
| version | For a standard tag, an identifier for the taxonomy; otherwise the accession number where the tag was defined. |
| ddate | The end date for the data value, rounded to the nearest month end. |
| qtrs | The count of the number of quarters represented by the data value, rounded to the nearest whole number. “0” indicates it is a point-in-time value. |
| uom | The unit of measure for the value. |
| segments | Tags used to represent axis and member reporting. |
| coreg | If specified, indicates a specific co-registrant, the parent company, or other entity (e.g., guarantor). NULL indicates the consolidated entity. |
| value | The value. This is not scaled, it is as found in the Interactive Data file, but is limited to four digits to the right of the decimal point. |
| footnote | The text of any superscripted footnotes on the value, as shown on the statement page, truncated to 512 characters, or if there is no footnote, then this field will be blank. |
| tag | version | custom | abstract | datatype | iord | crdr | tlabel | doc |
|---|---|---|---|---|---|---|---|---|
| Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest | us-gaap/2024 | 0 | 0 | monetary | D | C | Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest | Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners. |
| Proceeds From Issuance Of Commercial Paper | us-gaap/2024 | 0 | 0 | monetary | D | D | Proceeds from Issuance of Commercial Paper | The cash inflow from borrowing by issuing commercial paper. |
| Proceeds From Issuance Of Long Term Debt | us-gaap/2024 | 0 | 0 | monetary | D | D | Proceeds from Issuance of Long-Term Debt | The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer. |
| Divestituregainsandroyalties | 0000014272-25-000091 | 1 | 0 | monetary | D | C | Divestiture gains and royalties | This represents the amount of gains and royalties as a result of business divestitures. |
| Assets Current | us-gaap/2024 | 0 | 0 | monetary | I | D | Assets, Current | Amount of asset recognized for present right to economic benefit, classified as current. |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | us-gaap/2024 | 0 | 0 | monetary | I | D | Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents | Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. |
| Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax | us-gaap/2024 | 0 | 0 | monetary | D | C | Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax | Amount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness. |
| Payments To Acquire Businesses Net Of Cash Acquired | us-gaap/2024 | 0 | 0 | monetary | D | C | Payments to Acquire Businesses, Net of Cash Acquired | The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase. |
| Payments To Acquire Property Plant And Equipment | us-gaap/2024 | 0 | 0 | monetary | D | C | Payments to Acquire Property, Plant, and Equipment | The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets. |
| Stockholders Equity Including Portion Attributable To Noncontrolling Interest | us-gaap/2024 | 0 | 0 | monetary | I | C | Equity, Including Portion Attributable to Noncontrolling Interest | Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity. |
| Comprehensive Income Net Of Tax | us-gaap/2024 | 0 | 0 | monetary | D | C | Comprehensive Income (Loss), Net of Tax, Attributable to Parent | Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners. |
| Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest | us-gaap/2024 | 0 | 0 | monetary | D | D | Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest | Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners. |
| Available For Sale Securities Debt Securities Current | us-gaap/2024 | 0 | 0 | monetary | I | D | Debt Securities, Available-for-Sale, Current | Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current. |
| Deferred Income Tax Assets Net | us-gaap/2024 | 0 | 0 | monetary | I | D | Deferred Income Tax Assets, Net | Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting. |
| Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest | us-gaap/2024 | 0 | 0 | monetary | D | C | Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest | Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest. |
| Liabilities | us-gaap/2024 | 0 | 0 | monetary | I | C | Liabilities | Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others. |
| Liabilities And Stockholders Equity | us-gaap/2024 | 0 | 0 | monetary | I | C | Liabilities and Equity | Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any. |
| Payments Of Dividends | us-gaap/2024 | 0 | 0 | monetary | D | C | Payments of Dividends | Cash outflow in the form of capital distributions and dividends to common shareholders, preferred shareholders and noncontrolling interests. |
| Retained Earnings Accumulated Deficit | us-gaap/2024 | 0 | 0 | monetary | I | C | Retained Earnings (Accumulated Deficit) | Amount of accumulated undistributed earnings (deficit). |
| Accumulated Other Comprehensive Income Loss Net Of Tax | us-gaap/2024 | 0 | 0 | monetary | I | C | Accumulated Other Comprehensive Income (Loss), Net of Tax | Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source. |
| Additional Paid In Capital | us-gaap/2024 | 0 | 0 | monetary | I | C | Additional Paid in Capital | Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock. |
| Debt Current | us-gaap/2024 | 0 | 0 | monetary | I | C | Debt, Current | Amount of debt and lease obligation, classified as current. |
| Income Tax Expense Benefit | us-gaap/2024 | 0 | 0 | monetary | D | D | Income Tax Expense (Benefit) | Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations. |
| Increase Decrease In Receivables | us-gaap/2024 | 0 | 0 | monetary | D | C | Increase (Decrease) in Receivables | The increase (decrease) during the reporting period in the total amount due within one year (or one operating cycle) from all parties, associated with underlying transactions that are classified as operating activities. |
| Net Income Loss | us-gaap/2024 | 0 | 0 | monetary | D | C | Net Income (Loss) Attributable to Parent | The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. |
| Receivables Net Current | us-gaap/2024 | 0 | 0 | monetary | I | D | Receivables, Net, Current | The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value. |
| Stockholders Equity | us-gaap/2024 | 0 | 0 | monetary | I | C | Equity, Attributable to Parent | Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest. |
| Assets | us-gaap/2024 | 0 | 0 | monetary | I | D | Assets | Amount of asset recognized for present right to economic benefit. |
| Cost Of Goods And Services Sold | us-gaap/2024 | 0 | 0 | monetary | D | D | Cost of Goods and Services Sold | The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities. |
| Earnings Per Share Diluted | us-gaap/2024 | 0 | 0 | perShare | D | Earnings Per Share, Diluted | The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. | |
| Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | us-gaap/2024 | 0 | 0 | monetary | D | D | Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations | Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. |
| Other Assets Noncurrent | us-gaap/2024 | 0 | 0 | monetary | I | D | Other Assets, Noncurrent | Amount of noncurrent assets classified as other. |
| Acquired I P R D | 0000014272-25-000091 | 1 | 0 | monetary | D | D | Acquired IPRD | Acquired IPRD |
| Available For Sale Securities Debt Securities Noncurrent | us-gaap/2024 | 0 | 0 | monetary | I | D | Debt Securities, Available-for-Sale, Noncurrent | Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent. |
| Amortizationof Acquired Intangible Assets | 0000014272-25-000091 | 1 | 0 | monetary | D | D | Amortization of Acquired Intangible Assets | Amortization of Acquired Intangible Assets |
| Depreciation Depletion And Amortization | us-gaap/2024 | 0 | 0 | monetary | D | D | Depreciation, Depletion and Amortization | The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets. |
| Increase Decrease In Accrued Income Taxes Payable | us-gaap/2024 | 0 | 0 | monetary | D | D | Increase (Decrease) in Income Taxes Payable | The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction. |
| Increase Decrease In Other Operating Capital Net | us-gaap/2024 | 0 | 0 | monetary | D | C | Increase (Decrease) in Other Operating Assets and Liabilities, Net | Amount of increase (decrease) in operating assets after deduction of operating liabilities classified as other. |
| Liabilities Current | us-gaap/2024 | 0 | 0 | monetary | I | C | Liabilities, Current | Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer. |
| Proceeds From Sale And Maturity Of Available For Sale Securities | us-gaap/2024 | 0 | 0 | monetary | D | D | Proceeds from Sale and Maturity of Debt Securities, Available-for-Sale | Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). |
| Selling General And Administrative Expense | us-gaap/2024 | 0 | 0 | monetary | D | D | Selling, General and Administrative Expense | The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc. |
| Share Based Compensation | us-gaap/2024 | 0 | 0 | monetary | D | D | Share-Based Payment Arrangement, Noncash Expense | Amount of noncash expense for share-based payment arrangement. |
| Payments For Proceeds From Stock Option Exercises And Other Adjustments | 0000014272-25-000091 | 1 | 0 | monetary | D | D | Payments For (Proceeds From) Stock Option Exercises And Other Adjustments | Payments For (Proceeds From) Stock Option Exercises And Other Adjustments |
| Cash And Cash Equivalents At Carrying Value | us-gaap/2024 | 0 | 0 | monetary | I | D | Cash and Cash Equivalents, at Carrying Value | Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. |
| Equity Method Investment Realized Gain Loss On Disposal | us-gaap/2024 | 0 | 0 | monetary | D | C | Equity Method Investment, Realized Gain (Loss) on Disposal | Amount of gain (loss) on sale or disposal of an equity method investment. |
| Increase Decrease In Inventories | us-gaap/2024 | 0 | 0 | monetary | D | C | Increase (Decrease) in Inventories | The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities. |
| Other Comprehensive Income Loss Net Of Tax | us-gaap/2024 | 0 | 0 | monetary | D | C | Other Comprehensive Income (Loss), Net of Tax | Amount after tax and reclassification adjustments of other comprehensive income (loss). |
| Other Liabilities Current | us-gaap/2024 | 0 | 0 | monetary | I | C | Other Liabilities, Current | Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer. |
| Other Noncash Income Expense | us-gaap/2024 | 0 | 0 | monetary | D | C | Other Noncash Income (Expense) | Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other. |
| Preferred Stock Value | us-gaap/2024 | 0 | 0 | monetary | I | C | Preferred Stock, Value, Issued | Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity. |
| Profit Loss | us-gaap/2024 | 0 | 0 | monetary | D | C | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest | The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest. |
| Divestitureandotherproceeds | 0000014272-25-000091 | 1 | 0 | monetary | D | D | Divestiture and other proceeds | This element represents the cash inflow during the period from the sale of a business, asset or other proceeds. |
| Costs And Expenses | us-gaap/2024 | 0 | 0 | monetary | D | D | Costs and Expenses | Total costs of sales and operating expenses for the period. |
| Deferred Income Tax Expense Benefit | us-gaap/2024 | 0 | 0 | monetary | D | D | Deferred Income Tax Expense (Benefit) | Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations. |
| Goodwill | us-gaap/2024 | 0 | 0 | monetary | I | D | Goodwill | Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized. |
| Intangible Assets Net Excluding Goodwill | us-gaap/2024 | 0 | 0 | monetary | I | D | Intangible Assets, Net (Excluding Goodwill) | Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges. |
| Net Cash Provided By Used In Operating Activities | us-gaap/2024 | 0 | 0 | monetary | D | Net Cash Provided by (Used in) Operating Activities | Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities. | |
| Other Assets Current | us-gaap/2024 | 0 | 0 | monetary | I | D | Other Assets, Current | Amount of current assets classified as other. |
| Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax | us-gaap/2024 | 0 | 0 | monetary | D | C | OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax | Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale. |
| Other Liabilities Noncurrent | us-gaap/2024 | 0 | 0 | monetary | I | C | Other Liabilities, Noncurrent | Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer. |
| Proceeds From Other Short Term Debt | us-gaap/2024 | 0 | 0 | monetary | D | D | Proceeds from Other Short-Term Debt | Amount of cash inflow from short-term debt classified as other. |
| Proceeds From Sale Of Equity Securities Fv Ni | us-gaap/2024 | 0 | 0 | monetary | D | D | Proceeds from Sale of Equity Securities, FV-NI | Amount of cash inflow from sale of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as investing activity. |
| Inventory Net | us-gaap/2024 | 0 | 0 | monetary | I | D | Inventory, Net | Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer. |
| Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Net Of Tax | us-gaap/2024 | 0 | 0 | monetary | D | D | Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax | Amount, after tax and reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan. |
| Research And Development Expense | us-gaap/2024 | 0 | 0 | monetary | D | D | Research and Development Expense | Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. |
| Revenues | us-gaap/2024 | 0 | 0 | monetary | D | C | Revenues | Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss). |
| Accounts Payable Current | us-gaap/2024 | 0 | 0 | monetary | I | C | Accounts Payable, Current | Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect | us-gaap/2024 | 0 | 0 | monetary | D | D | Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect | Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. |
| Commitments And Contingencies | us-gaap/2024 | 0 | 0 | monetary | I | C | Commitments and Contingencies | Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur. |
| Deferred Income Tax Liabilities Net | us-gaap/2024 | 0 | 0 | monetary | I | C | Deferred Income Tax Liabilities, Net | Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting. |
| Increase Decrease In Accounts Payable | us-gaap/2024 | 0 | 0 | monetary | D | D | Increase (Decrease) in Accounts Payable | The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. |
| Net Cash Provided By Used In Financing Activities | us-gaap/2024 | 0 | 0 | monetary | D | D | Net Cash Provided by (Used in) Financing Activities | Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit. |
| Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax | us-gaap/2024 | 0 | 0 | monetary | D | C | Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss) Arising During Period, Net of Tax | Amount after tax, before reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature. |
| Long Term Debt Noncurrent | us-gaap/2024 | 0 | 0 | monetary | I | C | Long-Term Debt, Excluding Current Maturities | Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation. |
| Common Stock Value Outstanding | us-gaap/2024 | 0 | 0 | monetary | I | C | Common Stock, Value, Outstanding | Value of common shares held by shareholders. Excludes common shares repurchased and held as treasury shares. |
| Earnings Per Share Basic | us-gaap/2024 | 0 | 0 | perShare | D | Earnings Per Share, Basic | The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period. | |
| Increase Decrease In Other Accrued Liabilities | us-gaap/2024 | 0 | 0 | monetary | D | D | Increase (Decrease) in Other Accrued Liabilities | The increase (decrease) during the reporting period in other expenses incurred but not yet paid. |
| Net Cash Provided By Used In Investing Activities | us-gaap/2024 | 0 | 0 | monetary | D | D | Net Cash Provided by (Used in) Investing Activities | Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets. |
| Other Nonoperating Income Expense | us-gaap/2024 | 0 | 0 | monetary | D | C | Other Nonoperating Income (Expense) | Amount of income (expense) related to nonoperating activities, classified as other. |
| Payments To Acquire Marketable Securities | us-gaap/2024 | 0 | 0 | monetary | D | C | Payments to Acquire Marketable Securities | Amount of cash outflow for purchase of marketable security. |
| Treasury Stock Common Value | us-gaap/2024 | 0 | 0 | monetary | I | D | Treasury Stock, Common, Value | Amount allocated to previously issued common shares repurchased by the issuing entity and held in treasury. |
| Minority Interest | us-gaap/2024 | 0 | 0 | monetary | I | C | Equity, Attributable to Noncontrolling Interest | Amount of equity (deficit) attributable to noncontrolling interest. Excludes temporary equity. |
| Property Plant And Equipment Net | us-gaap/2024 | 0 | 0 | monetary | I | D | Property, Plant and Equipment, Net | Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. |
| Field Name | Field Description |
|---|---|
| tag | The unique identifier (name) for a tag in a specific taxonomy release. |
| version | For a standard tag, an identifier for the taxonomy; otherwise the accession number where the tag was defined. |
| custom | 1 if tag is custom (version=adsh), 0 if it is standard. Note: This flag is technically redundant with the version and adsh columns. |
| abstract | 1 if the tag is not used to represent a numeric fact. |
| datatype | If abstract=1, then NULL, otherwise the data type (e.g., monetary) for the tag. |
| iord | If abstract=1, then NULL; otherwise, “I” if the value is a point-in time, or “D” if the value is a duration. |
| crdr | If datatype = monetary, then the tag’s natural accounting balance (debit or credit); if not defined, then NULL. |
| tlabel | If a standard tag, then the label text provided by the taxonomy, otherwise the text provided by the filer. A tag which had neither would have a NULL value here. |
| doc | The detailed definition for the tag. If a standard tag, then the text provided by the taxonomy, otherwise the text assigned by the filer. Some tags have neither, and this field is NULL. |
| adsh | report | line | stmt | inpth | rfile | tag | version | plabel | negating |
|---|---|---|---|---|---|---|---|---|---|
| 0000014272-25-000091 | 2 | 7 | IS | 0 | H | Revenues | us-gaap/2024 | Total Revenues | 0 |
| 0000014272-25-000091 | 2 | 8 | IS | 0 | H | Cost Of Goods And Services Sold | us-gaap/2024 | Cost of products sold | 0 |
| 0000014272-25-000091 | 2 | 9 | IS | 0 | H | Selling General And Administrative Expense | us-gaap/2024 | Selling, general and administrative | 0 |
| 0000014272-25-000091 | 2 | 10 | IS | 0 | H | Research And Development Expense | us-gaap/2024 | Research and development | 0 |
| 0000014272-25-000091 | 2 | 11 | IS | 0 | H | Acquired I P R D | 0000014272-25-000091 | Acquired IPRD | 0 |
| 0000014272-25-000091 | 2 | 12 | IS | 0 | H | Amortizationof Acquired Intangible Assets | 0000014272-25-000091 | Amortization of acquired intangible assets | 0 |
| 0000014272-25-000091 | 2 | 13 | IS | 0 | H | Other Nonoperating Income Expense | us-gaap/2024 | Other (income)/expense, net | 1 |
| 0000014272-25-000091 | 2 | 14 | IS | 0 | H | Costs And Expenses | us-gaap/2024 | Total Expenses | 0 |
| 0000014272-25-000091 | 2 | 15 | IS | 0 | H | Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest | us-gaap/2024 | Earnings/(Loss) before income taxes | 0 |
| 0000014272-25-000091 | 2 | 16 | IS | 0 | H | Income Tax Expense Benefit | us-gaap/2024 | Income tax provision | 0 |
| 0000014272-25-000091 | 2 | 17 | IS | 0 | H | Profit Loss | us-gaap/2024 | Net earnings/(loss) | 0 |
| 0000014272-25-000091 | 2 | 18 | IS | 0 | H | Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest | us-gaap/2024 | Noncontrolling interest | 0 |
| 0000014272-25-000091 | 2 | 19 | IS | 0 | H | Net Income Loss | us-gaap/2024 | Net earnings/(loss) attributable to BMS | 0 |
| 0000014272-25-000091 | 2 | 21 | IS | 0 | H | Earnings Per Share Basic | us-gaap/2024 | Basic (usd per share) | 0 |
| 0000014272-25-000091 | 2 | 22 | IS | 0 | H | Earnings Per Share Diluted | us-gaap/2024 | Diluted (usd per share) | 0 |
| 0000014272-25-000091 | 3 | 1 | CI | 0 | H | Profit Loss | us-gaap/2024 | Net earnings/(loss) | 0 |
| 0000014272-25-000091 | 3 | 3 | CI | 0 | H | Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax | us-gaap/2024 | Derivatives qualifying as cash flow hedges | 0 |
| 0000014272-25-000091 | 3 | 4 | CI | 0 | H | Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Net Of Tax | us-gaap/2024 | Pension and postretirement benefits | 1 |
| 0000014272-25-000091 | 3 | 5 | CI | 0 | H | Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax | us-gaap/2024 | Marketable debt securities | 0 |
| 0000014272-25-000091 | 3 | 6 | CI | 0 | H | Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax | us-gaap/2024 | Foreign currency translation | 0 |
| 0000014272-25-000091 | 3 | 7 | CI | 0 | H | Other Comprehensive Income Loss Net Of Tax | us-gaap/2024 | Total other comprehensive income/(loss) | 0 |
| 0000014272-25-000091 | 3 | 8 | CI | 0 | H | Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest | us-gaap/2024 | Comprehensive income/(loss) | 0 |
| 0000014272-25-000091 | 3 | 9 | CI | 0 | H | Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest | us-gaap/2024 | Comprehensive income attributable to noncontrolling interest | 0 |
| 0000014272-25-000091 | 3 | 10 | CI | 0 | H | Comprehensive Income Net Of Tax | us-gaap/2024 | Comprehensive income/(loss) attributable to BMS | 0 |
| 0000014272-25-000091 | 4 | 3 | BS | 0 | H | Cash And Cash Equivalents At Carrying Value | us-gaap/2024 | Cash and cash equivalents | 0 |
| 0000014272-25-000091 | 4 | 4 | BS | 0 | H | Available For Sale Securities Debt Securities Current | us-gaap/2024 | Marketable debt securities | 0 |
| 0000014272-25-000091 | 4 | 5 | BS | 0 | H | Receivables Net Current | us-gaap/2024 | Receivables | 0 |
| 0000014272-25-000091 | 4 | 6 | BS | 0 | H | Inventory Net | us-gaap/2024 | Inventories | 0 |
| 0000014272-25-000091 | 4 | 7 | BS | 0 | H | Other Assets Current | us-gaap/2024 | Other current assets | 0 |
| 0000014272-25-000091 | 4 | 8 | BS | 0 | H | Assets Current | us-gaap/2024 | Total Current assets | 0 |
| 0000014272-25-000091 | 4 | 9 | BS | 0 | H | Property Plant And Equipment Net | us-gaap/2024 | Property, plant and equipment | 0 |
| 0000014272-25-000091 | 4 | 10 | BS | 0 | H | Goodwill | us-gaap/2024 | Goodwill | 0 |
| 0000014272-25-000091 | 4 | 11 | BS | 0 | H | Intangible Assets Net Excluding Goodwill | us-gaap/2024 | Other intangible assets | 0 |
| 0000014272-25-000091 | 4 | 12 | BS | 0 | H | Deferred Income Tax Assets Net | us-gaap/2024 | Deferred income taxes | 0 |
| 0000014272-25-000091 | 4 | 13 | BS | 0 | H | Available For Sale Securities Debt Securities Noncurrent | us-gaap/2024 | Marketable debt securities | 0 |
| 0000014272-25-000091 | 4 | 14 | BS | 0 | H | Other Assets Noncurrent | us-gaap/2024 | Other non-current assets | 0 |
| 0000014272-25-000091 | 4 | 15 | BS | 0 | H | Assets | us-gaap/2024 | Total Assets | 0 |
| 0000014272-25-000091 | 4 | 18 | BS | 0 | H | Debt Current | us-gaap/2024 | Short-term debt obligations | 0 |
| 0000014272-25-000091 | 4 | 19 | BS | 0 | H | Accounts Payable Current | us-gaap/2024 | Accounts payable | 0 |
| 0000014272-25-000091 | 4 | 20 | BS | 0 | H | Other Liabilities Current | us-gaap/2024 | Other current liabilities | 0 |
| 0000014272-25-000091 | 4 | 21 | BS | 0 | H | Liabilities Current | us-gaap/2024 | Total Current liabilities | 0 |
| 0000014272-25-000091 | 4 | 22 | BS | 0 | H | Deferred Income Tax Liabilities Net | us-gaap/2024 | Deferred income taxes | 0 |
| 0000014272-25-000091 | 4 | 23 | BS | 0 | H | Long Term Debt Noncurrent | us-gaap/2024 | Long-term debt | 0 |
| 0000014272-25-000091 | 4 | 24 | BS | 0 | H | Other Liabilities Noncurrent | us-gaap/2024 | Other non-current liabilities | 0 |
| 0000014272-25-000091 | 4 | 25 | BS | 0 | H | Liabilities | us-gaap/2024 | Total Liabilities | 0 |
| 0000014272-25-000091 | 4 | 26 | BS | 0 | H | Commitments And Contingencies | us-gaap/2024 | Commitments and Contingencies | 0 |
| 0000014272-25-000091 | 4 | 29 | BS | 0 | H | Preferred Stock Value | us-gaap/2024 | Preferred stock | 0 |
| 0000014272-25-000091 | 4 | 30 | BS | 0 | H | Common Stock Value Outstanding | us-gaap/2024 | Common stock | 0 |
| 0000014272-25-000091 | 4 | 31 | BS | 0 | H | Additional Paid In Capital | us-gaap/2024 | Capital in excess of par value of stock | 0 |
| 0000014272-25-000091 | 4 | 32 | BS | 0 | H | Accumulated Other Comprehensive Income Loss Net Of Tax | us-gaap/2024 | Accumulated other comprehensive loss | 0 |
| 0000014272-25-000091 | 4 | 33 | BS | 0 | H | Retained Earnings Accumulated Deficit | us-gaap/2024 | Retained earnings | 0 |
| 0000014272-25-000091 | 4 | 34 | BS | 0 | H | Treasury Stock Common Value | us-gaap/2024 | Less cost of treasury stock | 1 |
| 0000014272-25-000091 | 4 | 35 | BS | 0 | H | Stockholders Equity | us-gaap/2024 | Total BMS Shareholders equity | 0 |
| 0000014272-25-000091 | 4 | 36 | BS | 0 | H | Minority Interest | us-gaap/2024 | Noncontrolling interest | 0 |
| 0000014272-25-000091 | 4 | 37 | BS | 0 | H | Stockholders Equity Including Portion Attributable To Noncontrolling Interest | us-gaap/2024 | Total Equity | 0 |
| 0000014272-25-000091 | 4 | 38 | BS | 0 | H | Liabilities And Stockholders Equity | us-gaap/2024 | Total Liabilities and Equity | 0 |
| 0000014272-25-000091 | 5 | 2 | CF | 0 | H | Profit Loss | us-gaap/2024 | Net earnings/(loss) | 0 |
| 0000014272-25-000091 | 5 | 4 | CF | 0 | H | Depreciation Depletion And Amortization | us-gaap/2024 | Depreciation and amortization, net | 0 |
| 0000014272-25-000091 | 5 | 5 | CF | 0 | H | Deferred Income Tax Expense Benefit | us-gaap/2024 | Deferred income taxes | 0 |
| 0000014272-25-000091 | 5 | 6 | CF | 0 | H | Share Based Compensation | us-gaap/2024 | Stock-based compensation | 0 |
| 0000014272-25-000091 | 5 | 7 | CF | 0 | H | Divestituregainsandroyalties | 0000014272-25-000091 | Divestiture gains and royalties | 1 |
| 0000014272-25-000091 | 5 | 8 | CF | 0 | H | Acquired I P R D | 0000014272-25-000091 | Acquired IPRD | 0 |
| 0000014272-25-000091 | 5 | 9 | CF | 0 | H | Equity Method Investment Realized Gain Loss On Disposal | us-gaap/2024 | Equity investment (gains)/losses, net | 1 |
| 0000014272-25-000091 | 5 | 10 | CF | 0 | H | Other Noncash Income Expense | us-gaap/2024 | Other adjustments | 1 |
| 0000014272-25-000091 | 5 | 12 | CF | 0 | H | Increase Decrease In Receivables | us-gaap/2024 | Receivables | 1 |
| 0000014272-25-000091 | 5 | 13 | CF | 0 | H | Increase Decrease In Inventories | us-gaap/2024 | Inventories | 1 |
| 0000014272-25-000091 | 5 | 14 | CF | 0 | H | Increase Decrease In Accounts Payable | us-gaap/2024 | Accounts payable | 0 |
| 0000014272-25-000091 | 5 | 15 | CF | 0 | H | Increase Decrease In Other Accrued Liabilities | us-gaap/2024 | Rebates and discounts | 0 |
| 0000014272-25-000091 | 5 | 16 | CF | 0 | H | Increase Decrease In Accrued Income Taxes Payable | us-gaap/2024 | Income taxes payable | 0 |
| 0000014272-25-000091 | 5 | 17 | CF | 0 | H | Increase Decrease In Other Operating Capital Net | us-gaap/2024 | Other | 1 |
| 0000014272-25-000091 | 5 | 18 | CF | 0 | H | Net Cash Provided By Used In Operating Activities | us-gaap/2024 | Net cash provided by operating activities | 0 |
| 0000014272-25-000091 | 5 | 20 | CF | 0 | H | Proceeds From Sale And Maturity Of Available For Sale Securities | us-gaap/2024 | Sale and maturities of marketable debt securities | 0 |
| 0000014272-25-000091 | 5 | 21 | CF | 0 | H | Payments To Acquire Marketable Securities | us-gaap/2024 | Purchase of marketable debt securities | 1 |
| 0000014272-25-000091 | 5 | 22 | CF | 0 | H | Proceeds From Sale Of Equity Securities Fv Ni | us-gaap/2024 | Proceeds from sales of equity investments | 0 |
| 0000014272-25-000091 | 5 | 23 | CF | 0 | H | Payments To Acquire Property Plant And Equipment | us-gaap/2024 | Capital expenditures | 1 |
| 0000014272-25-000091 | 5 | 24 | CF | 0 | H | Divestitureandotherproceeds | 0000014272-25-000091 | Divestiture and other proceeds | 0 |
| 0000014272-25-000091 | 5 | 25 | CF | 0 | H | Payments To Acquire Businesses Net Of Cash Acquired | us-gaap/2024 | Acquisition and other payments, net of cash acquired | 1 |
| 0000014272-25-000091 | 5 | 26 | CF | 0 | H | Net Cash Provided By Used In Investing Activities | us-gaap/2024 | Net cash used in investing activities | 0 |
| 0000014272-25-000091 | 5 | 28 | CF | 0 | H | Proceeds From Issuance Of Commercial Paper | us-gaap/2024 | Proceeds from issuance of short-term debt obligations | 0 |
| 0000014272-25-000091 | 5 | 29 | CF | 0 | H | Proceeds From Other Short Term Debt | us-gaap/2024 | Other short-term financing obligations, net | 0 |
| 0000014272-25-000091 | 5 | 30 | CF | 0 | H | Proceeds From Issuance Of Long Term Debt | us-gaap/2024 | Proceeds from issuance of long-term debt | 0 |
| 0000014272-25-000091 | 5 | 31 | CF | 0 | H | Payments Of Dividends | us-gaap/2024 | Dividends | 1 |
| 0000014272-25-000091 | 5 | 32 | CF | 0 | H | Payments For Proceeds From Stock Option Exercises And Other Adjustments | 0000014272-25-000091 | Stock option proceeds and other, net | 0 |
| 0000014272-25-000091 | 5 | 33 | CF | 0 | H | Net Cash Provided By Used In Financing Activities | us-gaap/2024 | Net cash (used in)/provided by financing activities | 0 |
| 0000014272-25-000091 | 5 | 34 | CF | 0 | H | Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | us-gaap/2024 | Effect of exchange rates on cash, cash equivalents and restricted cash | 0 |
| 0000014272-25-000091 | 5 | 35 | CF | 0 | H | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect | us-gaap/2024 | Increase/(decrease) in cash, cash equivalents and restricted cash | 0 |
| 0000014272-25-000091 | 5 | 36 | CF | 0 | H | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | us-gaap/2024 | Cash, cash equivalents and restricted cash at beginning of period | 0 |
| 0000014272-25-000091 | 5 | 37 | CF | 0 | H | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | us-gaap/2024 | Cash, cash equivalents and restricted cash at end of period | 0 |
| Field Name | Field Description |
|---|---|
| adsh | Accession Number. The 20-character string formed from the 18-digit number assigned by the SEC to each EDGAR submission. |
| report | Represents the report grouping. This field corresponds to the statement (stmt) field, which indicates the type of statement. The numeric value refers to the “R file” as posted on the EDGAR Web site. |
| line | Represents the tag’s presentation line order for a given report. Together with the statement and report field, presentation location, order and grouping can be derived. |
| stmt | The financial statement location to which the value of the “report” field pertains. |
| inpth | Value was presented “parenthetically” instead of in columns within the financial statements. For example: Receivables (net of allowance for bad debts of $200 in 2012) $700. |
| rfile | The type of interactive data file rendered on the EDGAR web site, H = .htm file, X = .xml file. |
| tag | The tag chosen by the filer for this line item. |
| version | The taxonomy identifier if the tag is a standard tag, otherwise adsh. |
| plabel | The text presented on the line item, also known as a “preferred” label. |
| negating | Flag to indicate whether the plabel is negating. |